Effect of metformin and rosiglitazone in non-obese polycystic ovary syndrome women with insulin resistance
- Author:
- No author available
- Journal Title:
- Chinese Journal of Obstetrics and Gynecology
- Issue:
- 7
- DOI:
- 10.3760/cma.j.cn112141-20210424-00224
- Key Word:
- 多囊卵巢综合征;胰岛素抗药性;二甲双胍;罗格列酮;Polycystic ovary syndrome;Insulin resistance;Metformin;Rosiglitazone Clinical trial registration; Chinese Clinical Trial Registry, ChiCTR-TRC-130
Abstract： Objective:To investigate effects of metformin and rosiglitazone in non-obese polycystic ovary syndrome (PCOS) women with insulin resistance.Methods:Totally 200 non-obese PCOS women with insulin resistance in West China Second Hospital of Sichuan University were enrolled into this study from Sep. 2013 to Jun. 2016, and were randomly divided into two treatment groups: metformin group (1 500 mg/d) and rosiglitazone group (4 mg/d). The treatment lasted for 6 months. Their clinical and biochemical parameters were collected and compared.Results:In both groups, menstrual cycles [metformin group (37±4) days, rosiglitazone group (35±4) days] were shorter after treatment for 6 months (both P<0.01). After treatment for 6 months, body mass index [metformin group (21.6±1.6) kg/m 2, rosiglitazone group (21.7±1.7) kg/m 2] decreased in both groups (both P<0.01); decreased LH/FSH ratio (metformin group 1.67±0.80, rosiglitazone group 1.70±0.83) was also observed (both P<0.05). After treatment for 6 months, fasting insulin level [metformin group (13.5±5.1) mU/L, rosiglitazone group (12.7±5.6) mU/L] and homeostasis model assessment-insulin resistance index (metformin group 3.0±1.2, rosiglitazone group 2.8±1.2) were decreased in both groups (all P<0.01). Conclusions:For non-obese PCOS insulin resistance patients, screening of anthropometric and metabolic parameters is necessary. For PCOS with insulin resistance, lifestyle plus insulin sensitizers such as metformin could improve their clinical symptoms, correct the biochemical and metabolic dysfunction.
- [1]刘玉秀,姚晨,陈峰,等.非劣性/等效性试验的样本含量估计及统计推断[J].2003,(5).
- [2]杨冬梓,赵晓苗.多囊卵巢综合征的多学科干预和长期管理[J].2015,(11).
- [3]马良坤,金利娜,郁琦,等.生活方式调整及药物治疗多囊卵巢综合征的临床研究[J].2007,(5).
- [4]钟银秀,张国楠.二甲双胍降低多囊卵巢综合征患者子宫内膜癌发生风险的研究进展[J].2016,(8).
- [5]中华医学会妇产科学分会妇科内分泌学组.异常子宫出血诊断与治疗指南[J].2014,(11).
- [6]王笑臣,杨菁.重视多囊卵巢综合征患者的生活方式调整[J].2018,(1).
- [7]Sam Susan,Ehrmann David A..Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome[J].2017,60(9).
- [8]Hu, Lihua,Huang, Xiao,You, Chunjiao,etc.Prevalence of overweight, obesity, abdominal obesity and obesity-related risk factors in southern China.[J].2017,12(9).
- [9].Obesity: preventing and managing the global epidemic. Report of a WHO consultation.[J].2000,894.
- [10].Rosiglitazone, a Ligand to PPAR �� , Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation.[J].2019.
- [11]Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.[J].2007,356(24).
- [12]Ayvaz G,Tiras B,Toruner F,etc.The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.[J].2005,28(11).
- [13]Kyu Ri,Hwang.Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome.[J].2013,40.
- [14]Mahaffey,K.W.,Hafley,G.,Dickerson,S.,etc.Results of a reevaluation of cardiovascular outcomes in the RECORD trial[J].2013,166(2).
- [15].Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).[J].2004,19(1).
- [16]Panagiotis Anagnostis,Basil C. Tarlatzis,Robert P. Kauffman.Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences[J].2018,86.
- [17]中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J].2018,(1).
- [18]Li, Yujing,Tan, Jing,Wang, Qiuyi,etc.Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial[J].2020,113(1).
- [19]Qiu-yi Wang,Yong Song,Wei Huang,etc.Comparison of Drospirenone-with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial[J].2016,129(8).
- [20]Lara C, Morley,Thomas, Tang,Ephia, Yasmin,etc.Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.[J].2017,11(Spec ).
- [21]Juan Wang,Daichao Wu,Hui Guo,etc.Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome[J].2019,236.
- [22]Xin Huang,Qiuyi Wang,Tingting Liu,etc.Body fat indices as effective predictors of insulin resistance in obese/non-obese polycystic ovary syndrome women in the Southwest of China[J].2019,65(1).
- [23]Li,R.,Zhang,Q.,Yang,D.,etc.Prevalence of polycystic ovary syndrome in women in China: A large community-based study[J].2013,28(9).
- [24]Alberiche M,Kiechl S,Bonadonna RC,etc.Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.[J].1998,47(10).
- [25]Azziz R,Dumesic DA,Goodarzi MO.Polycystic ovary syndrome: an ancient disorder?[J].2011,95(5).